Objective: The objective of the work is to develop and validate a new, simple, highly sensitive RP-UPLC method for simultaneous estimation of Metolazone and Spironolactone in bulk and in its dosage forms.
Methods: The method was developed on a reversed-phase Hypersil Gold C18 (2.1Ã— 100 mm, 2.7 Âµm) column with isocratic elution. Detection was done by UV-Spectroscopy at a detection wavelength of 235 nm. The analytical procedure was validated by assessing the specificity, linearity, precision, accuracy, limit of detection, limit of quantification, robustness and ruggedness as per ICH guidelines.
Results: The results were obtained as follows- the retention times were found to be around 2.888 min and 3.835 min, the percentage purity was observed to be 99 % w/v and 100 % w/v, the percentage recovery was found to be 99.90% and 99.9% respectively for Metolazone and Spironolactone. Calibration plots were linear (r2 &gt; 0.999) over the concentration range of 12 to 28Î¼g/ml for Metolazolone and 120 to 280Î¼g/ml for Spironolactone. The LOD was 0.0002Âµg/ml for Metolazone and 0.01Âµg/ml for Spironolactone. The LOQ was found to be 0.0008Âµg/ml for Metolazone and 0.003Âµg/ml for Spironolactone.
Conclusion: The developed analytical method for the simultaneous quantitation of Metolazone and Spironolactone was found to be specific, rapid, reliable, and reproducible. No interference from any component of pharmaceutical dosage form was observed. The method is amenable to the routine analysis of large numbers of samples with good precision and accuracy

Chandrasekhar, K. B.

Gunasekaran, V.

Ismail, Y.

English

Innovare Academic Sciences: E-Journals

               Original Article  A NEW STABILITY INDICATING UPLC METHOD DEVELOPMENT AND VALIDATION FOR THE SIMULTANEOUS ESTIMATION OF METOLAZONE AND SPIRONOLACTONE IN BULK AND IN ITSPHARMACEUTICAL FORMULATIONSY. ISMAIL1* K. B. CHANDRASEKHAR2 V. GUNASEKARAN3, ,1JNIAS - JNTUA, Ananthapuramu, A. P. India, 2Director of Research and Development, Department ofChemistry, JNTUA, Anantapuramu, A. P. India, 3Sri Venkateswara College of Pharmacy, Chittoor, A. P, IndiaEmail: ismailpharmacy@yahoo.co.inReceived: 28 Aug 2014 Revised and Accepted: 30 Sep 2014  ABSTRACT Objective: The objective of the work is to develop and validate a new, simple, highly sensitive RP-UPLC method for simultaneous estimation of Metolazone and Spironolactone in bulk and in its dosage forms.  Methods: The method was developed on a reversed-phase Hypersil Gold C18 Results: The results were obtained as follows- the retention times were found to be around 2.888 min and 3.835 min, the percentage purity was observed to be 99 % w/v and 100 % w/v, the percentage recovery was found to be 99.90% and 99.9% respectively for Metolazone and Spironolactone. Calibration plots were linear (r(2.1× 100 mm, 2.7 µm) column with isocratic elution. Detection was done by UV-Spectroscopy at a detection wavelength of 235 nm. The analytical procedure was validated by assessing the specificity, linearity, precision, accuracy, limit of detection, limit of quantification, robustness and ruggedness as per ICH guidelines. 2Conclusion: The developed analytical  > 0.999) over the concentration range of 12 to 28μg/ml for Metolazolone and 120 to 280μg/ml for Spironolactone. The LOD was 0.0002µg/ml for Metolazone and 0.01µg/ml for Spironolactone. The LOQ was found to be 0.0008µg/ml for Metolazone and 0.003µg/ml for Spironolactone.  method for the simultaneous quantitation of Metolazone and Spironolactone was found to be specific, rapid, reliable, and reproducible. No interference from any component of pharmaceutical dosage form was observed. The methodKeywords: RP-UPLC, ICH, Metolazone, Spironolactone, UV-Spectroscopy, LOD, LOQ.  is amenable to the routine analysis of large numbers of samples with good precision and accuracy.  INTRODUCTION It was the Russian botanist Mikhail Tsvet (Mikhail Semyonovich Tsvet, 1872-1919) [1] who invented the first chromatography technique in 1901 during his research on chlorophyll. He used a liquid-adsorption column containing calcium carbonate to separate plant pigments. The method was described on December 30, 1901 at the XI Congress of Naturalists and Doctors in St. Petersburg. Chromatography is derived from Greek words “chroma” means “color” and “graphing” means “writing” in English [2,3].  UPLC system was designed to provide highest analysis speed and resolution and at the same time keep system pressure at a minimum. UPLC is up to 20 times faster than HPLC with same or better performance, 60% higher resolution, 10% more sensitive, Peak capacity is 1.4 % more, Reduced runtime from 60 to 20 min (related substances) and cut cost by 60%[4] thus this is the fastest, most efficient and cost effective LC system compared to HPLC.  Metolazone (MET) [5], with the chemical name 7-chloro-2-methyl-3-(2-methylphenyl)-4-oxo- 1, 2, 3, 4-tetrahydroquinazoline-6-sulfonamide (Fig.1) is a quinazoline diuretic, which is widely used in the treatment of hypertension. A proximal action of metolazone has been shown in humans by increased excretion of phosphate and magnesium ions and by a markedly increased fractional excretion of sodium in patients with severely compromised glomerular filtration.  Spironolactone (SPI)[6,7,8], with the chemical name 17-hydroxy-7α - mercapto-3-oxo-17α -pregn-4-ene-21-carboxylic acid γ-lactone acetate (Fig.2) is a renal competitive aldosterone antagonist in a class of pharmaceuticals called potassium-sparing diuretics. It causes increased amounts of sodium and water to be excreted, while potassium is retained. Spironolactone acts both as a diuretic and as an antihypertensive drug by this mechanism. It may be given alone or with other diuretic agents which act more proximally in the renal tubule. Aldosterone interacts with a cytoplasmic mineralocorticoid receptor to enhance the expression of the Na+, K+-ATPase and the Na+ channel involved in a Na+ K+ transport in the distal tubule. Spironolactone bind to this mineralocorticoid receptor, blocking the actions of aldosterone on gene expression. Aldosterone is a hormone; its primary function is to retain sodium and excrete potassium in the kidneys. Literature survey [9,10,11,12] revealed that no stability indicating UPLC method for simultaneous estimation of Metolazone and Spironolactone was reported. Hence the objective was to develop a stability indicating, simple, sensitive, accurate and precise method for Simultaneous Determination of Metolazone and Spironolactone in bulk and in its Pharmaceutical Dosage form by UPLC.   Fig. 1: Chemical Structure of Metolazone.   Fig. 2: Chemical Structure of Spironolactone. International Journal of Pharmacy and Pharmaceutical Sciences ISSN- 0975-1491              Vol 6, Issue 10, 2014 Innovare Academic Sciences Ismail et al. Int J Pharm Pharm Sci, Vol 6, Issue 10, 448-452 449 MATERIALS AND METHODS Chemicals and reagents Pure samples of Metolazone and Spironolactone were obtained from The Madras Pharmaceuticals, Chennai. The commercial samples of the tablets Metolactone containing Metolazone-5mg and Spironolactone-50mg were provided by CENTAUR Pharmaceuticals Pvt. .Ltd. HPLC grade Acetonitrile and Methanol were procured from Merck Ltd. (Mumbai, India.). Water (HPLC) was obtained from a Milli-QRO water purification system. All the other used reagents were of analytical grade. Chromatographic Conditions Chromatographic separation was achieved by using a Waters e2695 Separation Module UPLC system and a UV-visible detector. The chromatographic column utilized in the study was Hypersil Gold C1810 μl of standard and sample solutions were injected into the injector of UPLC, and the peak dareas of the drugs in standard and sample were compared and assay was performed. Metolazone and Spironolactone shows the percentage purity values of 99 % w/v and 100 % w/v respectively.  RESULTS AND DISCUSSION Specificity The specificity of the method was confirmed by injecting the placebo and placebo spiked standard and observed that there was no shift in wavelength interference due to placebo. This confirms the specificity of the proposed method. There is no peak in the blank and Placebo solution run at the retention time corresponding to Metolazone and Spironolactone as in standard run as shown in (Fig.3).  (2.1× 100 mm, 2.7 µm). Different mobile phases were tried, and the one containing Methanol, Acetonitrile and Phosphate Buffer (pH 3.5 adjusted with Orthophosphoric acid) in the ratio of 50:32:18 v/v was considered to be appropriate.  The mobile phase was filtered through 0.45μm membrane filter and ultra sonicated for 10 minutes. The flow rate selected was 1.0 ml/min with wave length of 235 nm. All the determinations were performed at constant column temperature (Ambient) and an injector volume is 10μl. The spectra were obtained from the UV detector.  Preparation of standard solution metolazone & spironolactone Accurately 5 mg Metolazone and 50 mg spironolactone were weighed and transferred into 50 ml volumetric flask, about 15 ml of diluent was added and sonicated for 30 minutes to dissolve it. The volume was made up with diluent. From this 5 ml of solution was pipetted out and transferred into 25 ml of volumetric flask and the volume was made up with diluents and it gives the concentration of 20 µg/ml Metolazone and 200 µg/ml spironolactone.  Preparation of sample solution metolazone & spironolactone Metalactone tablets containing 5mg metolazone and 50mg spironolactone were weighed and the average weight was calculated. The tablets were powdered in a mortar and a sample of powder equivalent to 5mg metolazone and 50mg spiranolactone was transferred into a 50 ml volumetric flask and 15 ml of diluent was added, sonicated for 30 min and made up to the mark with diluents. Pipette out 5 ml of above solution into 25 ml volumetric flask and made up with diluents to obtain a concentration of 20 µg/ml, 200 µg/ml of Metolazone and spironolactone respectively.  Assay  Fig. 3: chromatogram showing specificity of metolazone and spironolactone.  Linearity and range Linearity was evaluated by visual inspection of plot of peak are as a function of analyte concentrations for Metolazone and Spironolactone. From the linearity studies the specified range was determined for Metolazone and Spironolactone given as 12 - 28 μg/ml and 120-280 respectively. The results are reported in Table-1. The calibration curves are shown in (Fig.4 & 5).   Table 1: Linearity Results for Metolazone and Spironolactone Parameters  Metolazone Spironolactone Linear Dynamic Range 12-28μg/ml 120-280μg/ml Correlation Coefficient 0.999 0.999 Slope (m) 23957 2335   Fig. 4: Linearity of spironolactone  Fig. 5: Linearity of metolazone Ismail et al. Int J Pharm Pharm Sci, Vol 6, Issue 10, 448-452 450 Table 2: system precision data for Metolazone  Sample Name Name R Area T Height  Tailing Plate Count  1 Sys pre MET 2.880 462743 76652 1.0 5874 2 Sys pre MET 2.899 466576 76985 1.0 5833 3 Sys pre MET 2.888 467653 77300 1.0 5967 4 Sys pre MET 2.889 465737 76621 0.9 5834 5 Sys pre MET 2.890 463971 76647 0.9 5870 6 Sys pre MET 2.890 465863 76654 0.9 5798 Mean    465960 76841   Std. .Dev    1347 297   %RSD    0.3 0.4    Table 3: system precision data for Spironolactone  Sample Name Name R Area T Height Tailing Plate Count  1  Sys pre SPI 3.835 443864 59742 0.9 6716 2 Sys pre  SPI 3.837 444847 58975 0.9 6713 3 Sys pre  SPI 3.836 444064 59143 0.9 6742 4 Sys pre  SPI 3.837 447868 58651 0.9 6583 5 Sys pre  SPI 3.838 445701 58791 0.9 6763 6 Sys pre  SPI 3.838 449686 58839 0.9 6673 Mean    446433 58882   Std. .Dev    2308 185   %RSD    0.5 0.3    Table 4: Method precision data for Metolazone S. No. Sample Name Name RT Area Height 1 PRECISION MET 2.889 464597 76296 2 PRECISION  MET 2.890 463482 76027 3 PRECISION  MET 2.891 464533 75700 4 PRECISION  MET 2.890 466393 75544 5 PRECISION  MET 2.891 461733 75126 6 PRECISION  MET 2.889 466272 75181 Mean    464502 75646 Std. Dev.    1756 462 % RSD    0.4 0.6  Table 5: Method precision data for Spironolactone S. No. Sample Name Name RT Area Height 1 PRECISION  SPI 3.838 449484 58662 2 PRECISION  SPI 3.839 448445 58434 3 PRECISION  SPI 3.839 449133 58204 4 PRECISION  SPI 3.839 446001 57950 5 PRECISION  SPI 3.839 446901 57793 6 PRECISION  SPI 3.838 447322 57659 Mean    447881 58117 Std. Dev.    1361 387 % RSD    0.3 0.7  Table 6: Results of Precision for Metolazone & Spironolactone:  S. No. Sample weight Sample area-1 Sample area-2 % Assay-1  % Assay-2   1 242 464597 449484 99 101  2 242 463482 448445 98 100  3 242 464533 449133 99 101  4 242 466393 446001 99 100  5 242 461733 446901 98 100  6 242 466272 447322 99 100 Avg. assay    99 100  STD    0.37 0.30  % RSD    0.38 0.30  Precision  1) System precision The precision of the system was determined by six replicate injections of mixed standard solution. The % R. .S. .D of Area, retention time are present within the Acceptance criteria of 2 %. The results are reported in Table-2 & 3. The chromatograms are shown in (fig.6). 2) Method Precision The precision of the method was determined by six replicate injections of sample solution. The % R. S. D of Area and retention time and assay are present within the acceptance criteria of 2 %.  The results are reported in Table- 4, 5& 6. The chromatograms are shown in (fig.7). Ismail et al. Int J Pharm Pharm Sci, Vol 6, Issue 10, 448-452 451  Fig. 6: Chromatogram showing system precision   Fig. 7: Chromatogram showing method precision  Thus the proposed method was found to be high degree of precision and reproducibility.  D. System suitability System suitability parameters such as resolution, tailing factor, no. of theoretical plates were calculated and the results are presented in Table- 7. The chromatograms are shown in (fig-8). The resolution value of more than 2 indicates satisfactory results in quantitative work and the high resolution value obtained indicates the complete separation of the drugs. The tailing factor values for Metolazone and Spironolactone indicating the symmetrical nature of the peak. The no. of theoretical plates was high indicating the efficient performance of the column.   Table 7: System suitability parameters of Metolazone & Spironolactone Parameters Metolazone Spironolactone Tailing factor 1.0 0.9 Retention time 2.888 3.835 Theoretical plates per unit 5907 6717  E. Accuracy The validation of the proposed method was further verified by recovery studies. Acceptance criteria are 98 - 102 % w/v. The results are reported in Table - 8.   Table 8: Accuracy data for Metolazone and Spironolactone Parameters Metolazone Spironolactone % recovery 50 % 99.6 99.7 100 % 99.8 99.7 150 % 99.8 99.9  Fig. 8: chromatogram showing system suitability of metolazone and spironolactone.  This serves as a good index of the accuracy and reproducibility of the proposed method. F. Robustness  Robustness was determined by carrying out the assay during which flow rate and temperature were altered slightly. The results are reported in Table- 9.   Table 9: Robustness data for Metolazone and Spironolactone Parameters % RSD Metolazone % RSD Spironolactone Flow rate 0.2 0.3 Temperature  0.4 0.3 % RSD values for robustness indicated that the method is robust and does not show variations in the results on slight variations in flow rate and temperature.  G. Ruggedness Ruggedness was determined by carrying out the assay during under a variety of conditions, such as different laboratories, analysts, instruments, environmental conditions, operators and materials. There was reproducibility of test results under normal, expected operational conditions from laboratory and from analyst to analyst. The results are reported in Table - 10.  The method is rugged and does not show variations in the results on slight variations of parameters.  Table 10: Ruggedness data for Metolazone and Spironolactone  Parameters % RSD Metolazone % RSD Spironolactone Analyst 1 0.004 0.0003 Analyst 2  0.002 0.001 % RSD values for ruggedness indicated that the method is rugged and does not show variations in the results when performed by different analysts.  Limit of detection  The limit of detection of Metolazone and Spironolactone were calculated and found to be 0.0002 µg/ml and 0.011 µg/ml respectively.  Limit of quantification  The limit of quantification of Metolazone and Spironolactone were calculated and found to be 0.0008 µg/ml and 0.003 µg/ml respectively. Degradation studies degradation studies Degradation studies were carried out as per ICH guidelines. The sample solutions were subjected to acidic, basic, peroxide, water and light. Where as in acidic, basic the % degradations were found to be -7 %, -8 % and -9 %, -9 % for Metolazone and spironolactone respectively. The % degradation by peroxide was found to be -6 % Ismail et al. Int J Pharm Pharm Sci, Vol 6, Issue 10, 448-452 452 and -5 %. The % degradation by water was found to be -8 % and -7 %. The solid sample was subjected to light for 7 days and then the % degradation were found to be -5 % and -6 %. The results are reported in Table-11.  Table 11: Results of degradation studies for metolazone and spiranolactone S. No. Name Sample weight Sample area-1 Sample area-2 % Assay-1 % Assay-2 % DEG-1 % DEG-2 1 Acid 242 464433 449828 92 92 -7 -8 2 Base 242 463248 444682 90 91 -9 -9 3 Peroxide 242 464134 445453 93 95 -6 -5 4 Water 242 463892 444004 91 93 -8 -7 5 Light 242 462924 446801 94 94 -5 -6  CONCLUSION A new stability indicating analytical method is developed and validated for simultaneous estimation of Metolazone and Spironolactone by RP-UPLC technique. The sample preparation is simple, consumes less amount of mobile phase and the required time for analysis is very short, the information presented in the study could be very useful for the quality monitoring of metolazone and spironolactone in combined pharmaceutical dosage forms and can be used to check drug quality during stability testing. The analytical procedure is validated as per ICH guidelines and shown to be accurate, precise and specific. This method represents a fast analytical procedure for the simultaneous quantitation of Metolazone and Spironolactone. The method1. Ching Chowchan, Lee YC, Hernan Lam, Xue-Ming Zhang. Analytical method validation and instrument performance verification. 5th Edition; 2004. p. 248-50.  is amenable for the routine analysis of large numbers of samples with good precision and accuracy. CONFLICT OF INTERESTS  Declared None  REFERENCES 2. Frank Settle. Instrumental techniques for analytical chemistry, Prentice Hall. 3rd edition; 2004. p. 73-4. 3. Garry D. Christian. Analytical chemistry, 6th edition. John Wiley and Sons; 2003. p. 126-33.  4. Sharma BK. Instrumental methods of chemical analysis, Goel Publishing House, 25th edition; 2006. p. 286-8. 5. Aarti Chaudhary, KR Vadalia, Punam Thummer. Development and validation of ratio derivative spectrophotometric method for simultaneous estimation of Metolazone and Spironolactone in pharmaceutical dosage form. Int J Pharm Sci Res 2012;3:10. 6. WJ Bachaman, JT Stewart. HPLC-photolysis-electrochemical detection in pharmaceutical analysis: application to the determination of spironolactone and hydrochlorothiazide in tablets. J Chromatogr Sci 1990;28(3):123–8. 7. Bhojani Maulik, Dadhania Ketan, Faldu Shital. Development and validation of RP-HPLC method for simultaneous estimation of furosemide and spironolactone in their combined tablet dosage form. J Pharm Sci Biosci Res 2012;2(3):144-7. 8. Dana Muntean, Laurian Vlase, Silvia Imre, Marcela Achim, Daniela-Lucia Muntean. Determination of spironolactone and canrenone in human plasma by high-performance liquid chromatography with mass spectrometry detection. Croat Chem Acta 2011;84(3):361–6. 9. Devika GS, M Sudhakar, J Venkateshwara Rao, Ramesh petchi R. A simple RP-HPLC method for simultaneous estimation of torasemide and spirinolactone in tablets. J Pharm Res 2011;4(3):601-3. 10. Devika GS, M Sudhakar, J Venkateshwara Rao. RP-HPLC method for simultaneous estimation of Metolazone and Ramipril in oral solid dosage form. Int J Pharm Bio Sci 2012;3(4):193–200. 11. B Durga Prasad, B Chandra Kanth, R Vasanthi, M Ram Mohan, D Prabhakar. A Validated UV spectroscopic method of Metolazone in bulk and its tablet dosage forms. Int J Biol Pharm Res 2012;3(1):154-7. 12. Govind Kher, Vijay Ram, Mukesh Kher, Hitendra Joshi. Development and Validation of a HPTLC method for simultaneous determination of furosemide and spironolactone in its tablet formulation. Res J Pharm Biol Chem Sci 2013;4(1):365.  

A NEW STABILITY INDICATING UPLC METHOD DEVELOPMENT AND VALIDATION FOR THE SIMULTANEOUS ESTIMATION OF METOLAZONE AND SPIRONOLACTONE IN BULK AND IN ITS PHARMACEUTICAL FORMULATIONS

https://innovareacademics.in/journals/index.php/ijpps/article/download/2814/22998/180738

A NEW STABILITY INDICATING UPLC METHOD DEVELOPMENT AND VALIDATION FOR THE SIMULTANEOUS ESTIMATION OF METOLAZONE AND SPIRONOLACTONE IN BULK AND IN ITS PHARMACEUTICAL FORMULATIONS

Abstract

Similar works

Full text

Available Versions

Innovare Academic Sciences: E-Journals